Travere Therapeutics Inc (NASDAQ:TVTX) has a beta value of 0.70 and has seen 1.94 million shares traded in the last trading session. The company, currently valued at $1.38B, closed the last trade at $17.57 per share which meant it gained $0.07 on the day or 0.40% during that session. The TVTX stock price is -9.56% off its 52-week high price of $19.25 and 70.86% above the 52-week low of $5.12. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.29 million shares traded. The 3-month trading volume is 1.78 million shares.
The consensus among analysts is that Travere Therapeutics Inc (TVTX) is Buy stock at the moment, with a recommendation rating of 1.31. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 8 have rated it as a Hold, with 8 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.61.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Travere Therapeutics Inc (NASDAQ:TVTX) trade information
Sporting 0.40% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the TVTX stock price touched $17.57 or saw a rise of 7.04%. Year-to-date, Travere Therapeutics Inc shares have moved 95.44%, while the 5-day performance has seen it change 0.23%. Over the past 30 days, the shares of Travere Therapeutics Inc (NASDAQ:TVTX) have changed 28.72%. Short interest in the company has seen 8.11 million shares shorted with days to cover at 3.02.
Wall Street analysts have a consensus price target for the stock at $21.5, which means that the shares’ value could jump 18.28% from current levels. The projected low price target is $12.0 while the price target rests at a high of $30.0. In that case, then, we find that the current price level is -70.75% off the targeted high while a plunge would see the stock lose 31.7% from current levels.
Travere Therapeutics Inc (TVTX) estimates and forecasts
Figures show that Travere Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 180.67% over the past 6 months, with this year growth rate of 22.09%, compared to 17.50% for the industry. Revenue growth from the last financial year stood is estimated to be 56.90%.
15 analysts offering their estimates for the company have set an average revenue estimate of 69.39M for the current quarter. 5 have an estimated revenue figure of 68.28M for the next ending quarter. Year-ago sales stood 45.06M and 41.37M respectively for this quarter and the next, and analysts expect sales will grow by 54.00% for the current quarter and 56.90% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -12.34% over the past 5 years.
TVTX Dividends
Travere Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Travere Therapeutics Inc (NASDAQ:TVTX)’s Major holders
The top two institutional holders are BLACKROCK INC. with over 7.64 million shares worth more than $62.84 million. As of 2024-06-30, BLACKROCK INC. held 9.8642% of shares outstanding.
The other major institutional holder is ARMISTICE CAPITAL, LLC, with the holding of over 7.5 million shares as of 2024-06-30. The firm’s total holdings are worth over $61.65 million and represent 9.6774% of shares outstanding.
